எண்டோவாஸ்குலர் சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from எண்டோவாஸ்குலர் சிகிச்சை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In எண்டோவாஸ்குலர் சிகிச்சை Today - Breaking & Trending Today

Five-year Results Of The GORE® EXCLUDER® Iliac Branch Endoprosthesis Pivotal U.S. Multicenter Study Confirm Safety, Efficacy and Durability

Five-year Results Of The GORE® EXCLUDER® Iliac Branch Endoprosthesis Pivotal U.S. Multicenter Study Confirm Safety, Efficacy and Durability

Clot-retrieval device safe, effective for treatment of chronic thrombus in DVT at 30 days


Clot-retrieval device safe, effective for treatment of chronic thrombus in DVT at 30 days
Source:
Beasley R, et al. Late-breaking data and hot topics. Presented at: the International Symposium on Endovascular Therapy; May 9-11, 2021; Miami Beach, Florida (hybrid meeting).
Disclosures:
The study was funded by Inari Medical. Beasley reports he has financial ties with Abbott, Boston Scientific, Cardinal Health/Cordis, Centerline Biomedical, Cook Medical, C.R. Bard/BD, Cardiovascular Systems Inc., Endologix, Inari Medical, Medtronic, MicroMedical Solutions, Penumbra, Philips/Volcano/Spectranetics, Terumo/Boston Scientific and W.L. Gore and Associates.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on ....

United States , Coral Gables , Miami Beach , Roberte Beasley , Erik Swain , Palm Vascular Centers In Miami Beach , Micromedical Solutions , Cardiovascular Systems Inc , Cardinal Health Cordis , Boston Scientific , International Symposium On Endovascular Therapy , International Symposium , Endovascular Therapy , Centerline Biomedical , Cook Medical , Inari Medical , Palm Vascular Centers , Numeric Pain Rating Scale , ஒன்றுபட்டது மாநிலங்களில் , பவளம் கேபிள்கள் , மியாமி கடற்கரை , ஏறிக் ஸ்வைன் , இருதய அமைப்புகள் இன்க் , கார்டினல் ஆரோக்கியம் கோர்டிஸ் , போஸ்டன் அறிவியல் , சர்வதேச சிம்போசியம் ஆன் எண்டோவாஸ்குலர் சிகிச்சை ,

First patient treated in CereVasc clinical trial of eShunt™ System for communicating hydrocephalus


First patient treated in CereVasc clinical trial of eShunt™ System for communicating hydrocephalus
Investigational device has the potential to transform a half-century-old standard of care
News provided by
Share this article
Share this article
BOSTON, Feb. 10, 2021 /PRNewswire/ CereVasc, Inc., a clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, has treated the first patient in a study of its eShunt System, an investigational device intended to treat communicating hydrocephalus (CH), one of the most common neurological conditions worldwide. Representing the first minimally invasive treatment for CH, the eShunt device offers the potential to result in significant benefits over current treatment, a half-century-old neurosurgical procedure associated with frequent failure, infection risk and high costs. Study data will be available in 2021. ....

United States , Buenos Aires , Distrito Federal , El Salvador , Tufts Medical Center , Dan Levangie , Clinica Sagrada Familia , Carl Heilman , Pedro Lylyk , Adel Malek , Diana Gray , University Of Buenos Aires , University Of Ciencias Empresariales , Department Of Vascular Medicine , Department Of Neurosurgery , Hydrocephalus Association , University Of El Salvador , Endovascular Surgery Division At Tufts Medical Center , Prnewswire Cerevasc Inc , Cerevasc Co , Cerevasc Inc , Shunt System , Endovascular Surgery Division , Endovascular Treatment , Communicating Hydrocephalus , Principal Investigator ,